Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
No HPO annotations are available for this condition.
NR0B1-related adrenal hypoplasia congenita includes both X-linked adrenal hypoplasia congenita (X-linked AHC) and the phenotypes resulting from deletion of some of the genes in the Xp21 region: NR0B1 (causing X-linked AHC) and GK (glycerol kinase deficiency), and in some cases DMD (Duchenne muscular dystrophy).
NR0B1-related adrenal hypoplasia congenita includes both X-linked adrenal hypoplasia congenita (X-linked AHC) and Xp21 deletion (previously called complex glycerol kinase deficiency), which includes deletion of NR0B1 (causing X-linked AHC) and GK (causing glycerol kinase deficiency), and in some cases deletion of DMD (causing Duchenne muscular dystrophy).
NR0B1-related adrenal hypoplasia congenita should be suspected in males with the of X-linked adrenal hypoplasia congenita (X-linked AHC) or Xp21 deletion and supportive and findings.
No approved treatments are currently available for chromosome Xp21 deletion syndrome. The disease remains an area of unmet medical need.
To assess the extent of disease and needs in an individual diagnosed with NR0B1-related adrenal hypoplasia congenita, the following evaluations are recommended under the care of an experienced pediatric endocrinologist.
All Individuals with NR0B1-Related Adrenal Hypoplasia Congenita (X-linked AHC or Xp21 Deletion) Assessment of adrenal function:
If mineralocorticoid production is sufficient at the time of initial diagnosis, long-term follow up of adrenal mineralocorticoid function (sodium, potassium, aldosterone, plasma renin activity) is necessary. Monitoring should be fairly intense in the first two years of life (e.g., every 4 months) or at times of clinical concern. With age, mineralocorticoid sensitivity improves, but annual reviews would be appropriate and care needed during times of limited salt intake, fluid restriction, fluid loss (e.g., vomiting, diarrhea), or extreme heat. Clinical concern in the older child (e.g., postural hypotension or dizziness) needs investigation. If glucocorticoid production is sufficient at the time of initial diagnosis, long-term follow up of adrenal glucocorticoid function (basal ACTH, cortisol, cosyntropin test) is necessary. Basal ACTH is a useful marker of impaired glucocorticoid function and should be measured together with cortisol during the first two years of life. If there are any concerns, a cosyntropin stimulation test should be performed, looking for an impaired cortisol response, not just an inadequate basal cortisol level. Annual reviews of basal ACTH/cortisol and possibly cosyntropin stimulation should be considered in a boy with a genuine X-linked AHC if glucocorticoid insufficiency has not yet developed. Any clinical concerns (e.g.
No clinical trials have been registered for chromosome Xp21 deletion syndrome.
11 publications have been identified in PubMed for chromosome Xp21 deletion syndrome. Research spans Case Report / Case Series (55%), Review / Meta-Analysis (27%), and Diagnostic / Biomarker (9%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 6 | 55% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 10:55 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about chromosome Xp21 deletion syndrome
Source: GeneReviews — "NR0B1-Related Adrenal Hypoplasia Congenita"
X-linked AHC and Xp21 deletion
Source: GeneReviews — "NR0B1-Related Adrenal Hypoplasia Congenita"
In males with salt-losing primary adrenal insufficiency and either a family history of X-linked adrenal insufficiency or other features of NR0B1-related X-linked AHC (e.g., hypogonadotropic hypogonadism), the likelihood of identifying a pathogenic NR0B1 variant is increased . In contrast, in males with salt-losing primary adrenal insufficiency with no family history of adrenal insufficiency and no other features of NR0B1-related X-linked AHC in whom other causes of primary adrenal insufficiency have been excluded (e.g., congenital adrenal hyperplasia), the likelihood of identifying a pathogenic NR0B1 variant is about 20%-40% [, , , ].
Source: GeneReviews — "NR0B1-Related Adrenal Hypoplasia Congenita"
Biomarker and diagnostic research for chromosome Xp21 deletion syndrome has been reported in the published literature.
If the presentation is predominantly mineralocorticoid insufficiency (salt loss), assess adrenal glucocorticoid function (basal ACTH, cortisol, cosyntropin test). If function is reduced, appropriate glucocorticoid replacement is needed . If it is adequate, long-term follow up is necessary .
If the presentation is predominantly glucocorticoid insufficiency, assess adrenal mineralocorticoid function (sodium, potassium, aldosterone, plasma renin activity). If function is reduced, fludrocortisone replacement is required as well as adequate salt supplementation in young children (age 1 year) . If it is adequate, long-term follow up is necessary .
Assessment for early puberty or hypogonadotropic hypogonadism:
Source: GeneReviews — "NR0B1-Related Adrenal Hypoplasia Congenita"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "NR0B1-Related Adrenal Hypoplasia Congenita"
View trials for chromosome Xp21 deletion syndrome
Source: GeneReviews — "NR0B1-Related Adrenal Hypoplasia Congenita"
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
Research summaries
3 |
27% |
Testing and diagnosis research | 1 | 9% |
Laboratory research | 1 | 9% |
Gau M (2026). [PMID: 41285479](https://pubmed.ncbi.nlm.nih.gov/41285479/). *Endocr J*. [Review / Meta-Analysis]
Banerjee S (2025). [PMID: 40353385](https://pubmed.ncbi.nlm.nih.gov/40353385/). *Pediatr Endocrinol Diabetes Metab*. [Basic Science / Preclinical]
Yokohama Y (2025). [PMID: 40147472](https://pubmed.ncbi.nlm.nih.gov/40147472/). *J Obstet Gynaecol Res*. [Case Report / Case Series]
Mohamed AM (2025). [PMID: 40074450](https://pubmed.ncbi.nlm.nih.gov/40074450/). *J Genet Eng Biotechnol*. [Diagnostic / Biomarker]
Stanković S (2025). [PMID: 41199733](https://pubmed.ncbi.nlm.nih.gov/41199733/). *Acta Myol*. [Case Report / Case Series]
Marques L (2025). [PMID: 41583306](https://pubmed.ncbi.nlm.nih.gov/41583306/). *Cureus*. [Case Report / Case Series]
Bregvadze K (2025). [PMID: 40171039](https://pubmed.ncbi.nlm.nih.gov/40171039/). *Clin Med Insights Endocrinol Diabetes*. [Case Report / Case Series]
Singin B (2025). [PMID: 40103355](https://pubmed.ncbi.nlm.nih.gov/40103355/). *J Clin Res Pediatr Endocrinol*. [Review / Meta-Analysis]
Bu C (2025). [PMID: 39928819](https://pubmed.ncbi.nlm.nih.gov/39928819/). *Medicine (Baltimore)*. [Case Report / Case Series]
Kalashnikova TP (2025). [PMID: 40350738](https://pubmed.ncbi.nlm.nih.gov/40350738/). *Zh Nevrol Psikhiatr Im S S Korsakova*. [Case Report / Case Series]